-------------------------------------------------------------------------
Net loss and comprehensive loss
for the period (3,324,691) (3,812,759)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Basic and diluted net loss per share (0.05) (0.06)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted-average number of common shares
outstanding 67,194,886 61,880,544
Bioniche Life Sciences Inc.
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited - see going concern uncertainty)
For the three months ended September 30
2008 2007
$ $
-------------------------------------------------------------------------
OPERATING ACTIVITIES
Net loss for the period (3,324,691) (3,812,759)
Add (deduct) non cash items:
Amortization 911,612 531,082
Unrealized foreign exchange gain (93,758) (75,117)
Change in unrealized loss (gain) on
foreign currency embedded derivatives 59,693 (182,656)
Accreted interest on discounted receivables (9,788) -
Stock-based compensation 62,093 84,746
Warrants issued to consultants 700 -
Employee share ownership plan 177,423 147,769
-----
'/>"/>
| SOURCE Bioniche Life Sciences Inc. Copyright©2008 PR Newswire. All rights reserved |